News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Abmaxis, Inc. And MaimoniDex To Collaborate On Rheumatoid Arthritis Treatment


10/19/2005 5:08:52 PM

SANTA CLARA, Calif. and JERUSALEM, Sept. 21 /PRNewswire/ -- Abmaxis, Inc., a privately held biopharmaceutical company, and MaimoniDex RA Ltd., a biotechnology company focused on the treatment of rheumatoid arthritis with disease specific anti-CD44 monoclonal antibodies, announced today that they have signed an agreement to jointly develop a therapeutic human monoclonal antibody for the treatment of rheumatoid arthritis (RA) and other inflammatory diseases.

Based on its discovery of a disease-causing molecule found only in the joints of RA patients, MaimoniDex has developed a murine monoclonal antibody that has shown bioactivities both in vitro and in vivo. Using its unique antibody engineering technology, Abmaxis will humanize and optimize the murine antibody to develop a drug candidate suitable for potential therapeutic use. Under the terms of the agreement, MaimoniDex will pay Abmaxis an upfront technology license fee and Abmaxis is also entitled to receive future milestone payments and royalties on product sales.

"Working with Abmaxis, a specialist in antibody humanization and optimization with an excellent track record of successful partnerships, will enable the production of a commercially viable humanized monoclonal antibody for treating rheumatoid arthritis," commented Dr. Itshak Golan, President and Chief Executive Officer of MaimoniDex. "We are confident that their structure-centric approach can deliver a superior product in a timely manner."

"We believe that the MaimoniDex target is very important, as it is directly associated with inflammatory cells in rheumatoid arthritis patients," stated Peter Luo, Ph.D., Chief Technology Officer of Abmaxis.

About Abmaxis

Abmaxis Inc. is a privately held biopharmaceutical company located in Santa Clara, California, dedicated to the discovery, optimization and development of monoclonal antibody (MAb) products for human therapeutics and diagnostics. Abmaxis in-silico Immunization (AISIM(TM)) is a breakthrough antibody-engineering technology with external validation from eight corporate partnerships. We collaborate with corporate partners who have proprietary targets or antibodies that require humanization and engineering. We continue to seek corporate partnering opportunities. For more information, please visit our website: www.abmaxis.com or contact CJ Wang, Vice President of Business Development, at cjwang@abmaxis.com or 408-988-6100, x101.

About MaimoniDex

MaimoniDex is an Israeli biotech company focused on discovering disease-specific targets for a variety of major diseases. MaimoniDex's core business is: Treatment of Rheumatoid Arthritis (RA) with disease specific anti-CD44 monoclonal antibodies. The company was founded by Prof. David Naor and Dr. Itshak Golan of the department of Immunology at the Hebrew University and Hadassah Medical School in Jerusalem. For further information, please contact Dr. Itshak Golan, Ph.D., CEO. Tel: 972-3-531-2621, Mobile: 972-54-655-2073. Fax: 972-3-5341650, at igolan@radbiomed.com.

Abmaxis, Inc.

CONTACT: Shirley Clayton, Chief Executive Officer of Abmaxis, Inc.,+1-408-988-6100, ext. 130, or sclayton@abmaxis.com


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES